Discovery of a Selective BET Inhibitor for Treating Osteoarthritis
Bromodomain and extra-terminal domain (BET) family proteins are key regulators of gene transcription and have been implicated in a wide range of diseases, making these proteins a potential therapeutic target. Abnormal BET protein activity has been linked to cancer, inflammatory disorders, viral infections, and neurodegenerative conditions.
In a recent publication, researchers highlight the discovery of a selective BET inhibitor, BBC0906. The authors demonstrate that BBC0906 attenuated cartilage degradation and alleviated osteoarthritis (OA) in an OA mouse model. Significantly, BBC0906 was discovered from WuXi AppTec’s DNA-encoded library (DEL), demonstrating the versatility of DEL and DEL screening at WuXi AppTec.
Related Content
Target deconvolution, particularly when paired with proteomics techniques, plays a crucial role in drug discovery and target identification. By using...
VIEW RESOURCEDNA-encoded libraries have become widely used in drug discovery, and several approaches for linking chemical compounds to DNA have been...
VIEW RESOURCE